Journal article
Short-Course Low-Dose Primaquine for Radical Cure in G6PD-Normal Patients in the Pre-Elimination Context of Nepal
P Ghimire, G Dahal, N Adhikari, KR Rijal, S Adhikari, MR Banjara, H Mnjala, G Lee, S Weston, A Rumaseb, A Rai, B Ley, MS Hossain, JA Simpson, M Rajasekhar, B Adhikari, RN Price, BK Lal, K Thriemer
Tropical Medicine and International Health | Published : 2026
DOI: 10.1111/tmi.70145
Abstract
Background: Plasmodium vivax remains a challenge for malaria elimination in Nepal due to its ability to relapse. Radical cure with primaquine is effective but limited by poor adherence to the standard 14-day low-dose regimen. In 2022, the WHO recommended administering the same total dose (3.5 mg/kg) over 7 days to improve adherence. This study aimed to evaluate the 7-day low-dose primaquine regimen in G6PD-normal patients with uncomplicated P. vivax and/or P. falciparum malaria in the pre-elimination context of Nepal. Methods: A randomised study was conducted in south-west Nepal. Adult patients with microscopically confirmed P. vivax and/or P. falciparum malaria and glucose-6-phosphate dehyd..
View full abstractRelated Projects (2)
Grants
Awarded by Bill and Melinda Gates Foundation
Awarded by National Health and Medical Research Council (NHMRC)
Awarded by National Health and Medical Research Council (NHMRC) Leadership Investigator Grants
Awarded by National Health and Medical Research Council (NHMRC) Synergy Grant
Awarded by National Health and Medical Research Council (NHMRC) Center for Research Excellence